MORE ABOUT MAQUI BERRY

Science Behind Maqui

From nature to clinical validation — uncovering the molecular science that powers Maqui Berry’s extraordinary antioxidant and anti-inflammatory potential.

Over 15 years of clinical and pre-clinical research have confirmed the unique biological activity of Maqui’s delphinidins — molecules that connect the resilience of Patagonia with the future of nutraceutical Maqui Berry science.

For centuries, the Maqui Berry was revered by local Patagonian communities as a source of vitality and endurance.
Today, modern science has confirmed what tradition long observed: Maqui Berry contains the highest concentration of delphinidins found in any known fruit — up to 1,260 mg per 100 g of raw fruit, compared to just 97 mg in bilberries and 70 mg in grapes.

This exceptional profile translates into one of the world’s most powerful antioxidant performances, measured at 28,200 ORAC units, or 7× more than Açai and 9× more than Goji.

Maqui’s anthocyanin profile is composed of approximately 75 % delphinidins and 25 % cyanidins, giving it its deep violet pigment and superior bioactivity.

These findings inspired MNL Group to pioneer standardized Maqui extracts that deliver consistent potency, purity, and scientifically validated results.

Delphinidins — a subclass of anthocyanins — are responsible for Maqui’s intense color and its remarkable antioxidant and anti-inflammatory capacity.

They are recognized as the most potent natural anthocyanins, capable of scavenging over 40 % of DPPH radicals within 4 minutes, outperforming cyanidin and pelargonidin.

Their molecular structure enables them to:

Neutralize reactive oxygen species (ROS) and inhibit lipid peroxidation.
Downregulate NF-κB, reducing inflammatory responses.
Activate PPARγ receptors, improving glucose metabolism and insulin sensitivity.

Laboratory studies also confirm full-spectrum antioxidant activity, neutralizing all five major reactive oxygen species — peroxyl, hydroxyl, peroxynitrite, singlet oxygen, and superoxide — with an ORAC 5.0 value of 30,852 µmol Trolox equivalents/g (Brunswick Labs, USA).

- Reduced oxidized LDL and F2-isoprostanes in smokers (J. Am. Coll. Nutr., 2015).
- Improved HDL and lowered LDL by ~14 % after 90 days (Pan Minerva Medica, 2016).
- Lowered HbA1c from 5.65 % → 5.35 % in prediabetic subjects (Pan Minerva Medica, 2016).
- Significantly reduced postprandial glucose peaks within 60 minutes (Clinical Nutrition, 2013).
- Increased tear fluid secretion by 25 % vs placebo after 4 weeks (Takara Clinic, Japan, 2017).
- Reduced dry-eye symptom severity by ~75 % after 60 days.
- Demonstrated bioavailability of delphinidin D3G5G in lacrimal gland cells, protecting against oxidative stress.
- +39 % increase in skin elasticity after 90 days (collagen + Delphinol®).
- +22 % increase in dermal thickness measured by ultrasound.
- 90 % of participants reported visible improvement in skin firmness (Clin. Cosmet. Investig. Dermatol., 2018).
- PCT/IB2010/002698 – Antioxidant and metabolic applications.
- WO/2014/098092 – Dry eye therapy (MaquiBright®).
- PCT/IB2024/051136 – Prevention of muscle aging and sarcopenia.